ArticleDrug design, development and therapy2026
Population Pharmacokinetics and Model-Informed Precision Dosing of Lenalidomide Incorporating Total and Unbound Plasma Concentrations in Renally Impaired Patients with Multiple Myeloma.
Article in Drug design, development and therapy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: To develop a population pharmacokinetic (PK) model of lenalidomide and propose model-informed precision dosing based on total and unbound concentrations in multiple myeloma (MM) patients with moderate-to-severe renal impairment (RI). Patients and Methods: Thirty MM patients orally receiving lenalidomide were prospectively enrolled with the following stratification based on renal function: 11 with an estimated glomerular filtration rate [eGFR] < 30 mL/min/1.73 m Results: A two-compartment model with linear protein binding best described both total and unbound plasma lenalidomide concentration-time data. Apparent unbound clearance (CL/F) increased with higher eGFR and body surface area (BSA), while apparent central volume of distribution (V Conclusion: Our model identifies eGFR and BSA as critical covariates for precision dosing of lenalidomide to optimize therapeutic exposure in MM patients with RI.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.